A new 12-gene diagnostic biomarker signature of melanoma revealed by integrated microarray analysis

PeerJ

Volumn 2013, Issue 1, 2013, Pages

  Liu, Wanting ^a   Peng, Yonghong ^a   Tobin, Desmond J ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

Bioinformatics; Gene biomarker; Genome; Immunochemistry; Melanocytes; Melanoma; Metastasis; Microarray; Nevi; Skin

Indexed keywords

CALCINEURIN; COLLAGEN TYPE 11; CXCL13 CHEMOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOPROTEIN PHOSPHATASE 2; PROTEIN TYROSINE PHOSPHATASE; TENASCIN; TUMOR MARKER; WNT4 PROTEIN;

ADULT; ARTICLE; CALCIUM SIGNALING; CONTROLLED STUDY; EPIDERMIS; FEMALE; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; GENE INTERACTION; GENETIC ASSOCIATION; GENOME ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MELANOCYTE; MELANOMA; MELANOMA CELL; META ANALYSIS (TOPIC); MICROARRAY ANALYSIS; SRC HOMOLOGY DOMAIN; VALIDATION STUDY; WNT SIGNALING PATHWAY;

EID: 84877102953     PISSN: None     EISSN: 21678359     Source Type: Journal    
DOI: 10.7717/peerj.49     Document Type: Article

References (53)

1. Barrett T, Troup DB,Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH, Sherman PM,Muertter RN, Edgar R. 2011. NCBI GEO: archive for functional genomics datasets- 10 years on. Nucleic Acids Research 39:D1005-D1010
2. Bittner M,Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M, Radmacher M, Simon R, Yakhini Z, Ben-Dor A, Sampas N, Dougherty E,Wang E,Marincola F, Gooden C, Lueders J, Glatfelter A, Pollock P, Carpten J, Gillanders E, Leja D, Dietrich K, Beaudry C, Berens M, Alberts D, Sondak V. 2000. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406:536-540
3. Brown MP, Grundy WN, Lin D, Cristianini N, Sugnet CW, Furey TS, Ares M, Haussler D. 2000. Knowledge-based analysis of microarray gene expression data by using support vector machines. Proceedings of the National Academy of Sciences of the United States of America 97:262-267.
4. Carretero R,Wang E, Rodrguez AI, Reinboth J, Ascierto ML, Engle AM, Liu H, Camacho FM, Marincola FM, Garrido F, Cabrera T. 2011. Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes. International Journal of Cancer 131:387-395.
5. Choi JK, Yu U, Kim S, Yoo OJ. 2003. Combining multiple microarray studies and modeling interstudy variation. Bioinformatics 19:i84-i91.
6. Cochran J, Conn VS. 2008. Meta-analysis of quality of life outcomes following diabetes self-management training. Diabetes Education 34:815-823.
7. Eigentler T, Garbe C. 2006. Malignant melanoma: classification and staging of malignant melanoma. Frontiers of Radiation Therapy and Oncology 39:149-158.
8. Fagiani E, Giardina G, Luzi L, Cesaroni M, Quarto M, Capra M, Germano G, Bono M, Capillo M, Pelicci P, Lanfrancone L. 2007. RaLP, a new member of the Src homology and collagen family, regulates cell migration and tumor growth of metastatic melanomas. Cancer Research 67:3064-3073.
9. Fedida-Metula S, Feldman B, Koshelev V, Levin-Gromiko U, Voronov E, Fishman D. 2012. Lipid rafts couple store-operated Ca2C entry to constitutive activation of PKB/Akt in a Ca2C/calmodulin-, Src- and PP2A-mediated pathway and promote melanoma tumor growth. Carcinogenesis 33(4):740-750.
10. Flaherty KT,McArthur G. 2010. BRAF, a target in melanoma: implications for solid tumor drug development. Cancer 116:4902-4913.
11. Garraway LA,Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J, Lee C,Wagner SN, Li C, Golub TR, Rimm DL,Meyerson ML, Fisher DE, Sellers WR. 2005. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436:117-122.
12. Gledhill K, Rhodes LE, Brownrigg M, Haylett AK,Masoodi M, Thody AJ, Nicolaou A, Tobin DJ. 2010. Prostaglandin-E2 is produced by adult human epidermal melanocytes in response to UVB in a melanogenesis-independent manner. Pigment Cell Melanoma Research 23(3):394-403.
13. Goel VK, Lazar AJ,Warneke CL, Redston MS, Haluska FG. 2006. Examination of mutations in BRAF, NRAS and PTEN in primary cutaneous melanoma. Journal of Investigative Dermatology 126:154-160.
14. Gremel G, Rafferty M, Lau TYK, Gallagher WM. 2009. Identification and functional validation of therapeutic targets for malignant melanoma. Critical Reviews in Oncology/Hematology 72:194-214.
15. Guntur AR, Reinhold MI, Cuellar JJr, Naski MC. 2011. Conditional ablation of Pten in osteoprogenitors stimulates FGF signaling. Development 138:1433-1444.
16. Hocker T, Tsao H. 2007. Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Human Mutation 28:578-588.
17. Hoek K, Rimm DL,Williams KR, Zhao H, Ariyan S, Lin A, Kluger HM, Berger AJ, Cheng E, Trombetta ES,Wu T, Niinobe M, Yoshikawa K, Hannigan GE, Halaban R. 2004. Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Research 64:5270-5282.
18. Hoek KS. 2007. DNA microarray analysis of melanoma gene expression: a decade in the mines. Pigment Cell Research 20:466-484.
19. Hong F, Breitling R. 2008. A comparison of meta-analysis methods for detecting differentially expressed genes in microarray experiments. Bioinformatics 24:374-382.
20. Hosack DA, Dennis GJr, Sherman BT, Lane HC, Lempicki RA. 2003. Identifying biological themes within lists of genes with EASE. Genome Biology 4:R70.
21. Jaeger J, Koczan D, Thiesen HJ, Ibrahim SM, Gross G, Spang R, Kunz M. 2007. Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissue. Clinical Cancer Research 13:806-815.
22. John T, Black MA, Toro TT, Leader D, Gedye CA, Davis ID, Guilford PJ, Cebon JS. 2008. Predicting clinical outcome through molecular profiling in stage III melanoma. Clinical Cancer Research 14:5173-5180.
23. Junta CM, Sandrin-Garcia P, Fachin-Saltoratto AL,Mello SS, Oliveira RD, Rassi DM, Giuliatti S, Sakamoto-Hojo ET, Louzada-Junior P, Donadi EA, Passos GA. 2008. Different gene expression of peripheral blood mononuclear cells from rheumatoid arthritis patients may discriminate immunogenetic, pathogenic and treatment features. Immunology 127:365-372.
24. Jurman G,Merler S, Barla A, Paoli S, Galea A, Furlanello C. 2008. Algebraic stability indicators for ranked lists in molecular profiling. Bioinformatics 24:258-264.
25. Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M. 2012. KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Research 40:D109-D114.
26. Koh SS,Wei JP, Li X, Huang RR, Doan NB, Scolyer RA, Cochran AJ, Binder SW. 2012. Differential gene expression profiling of primary cutaneous melanoma and sentinel lymph node metastases. Modern Pathology 25(6):828-837.
27. Lens M. 2008. Current clinical overview of cutaneous melanoma. British Journal of Nursing 17:300-305.
28. Lukk M, Kapushesky M, Nikkilä J, Parkinson H, Goncalves A, Huber W, Ukkonen E, Brazma A. 2010. A global map of human gene expression. Nature Biotechnology 28:322-324.
29. Mann GJ, Pupo GM, Campain AE. 2013. BRAF mutation, NRAS mutation and absence of an immune-related expressed gene profile predict poor outcome in surgically resected stage III melanoma. Journal of Investigative Dermatology 133:509-517.
30. Miller AJ,Mihm MC. 2006. Mechanisms of Diseases: Melanoma. New England Journal of Medicine 355:51-65.
31. Miyamoto J, Berkowitz Z, Jones SE, Saraiya M. 2012. Indoor tanning device use among male high school students in the United States. Journal of Adolescent Health 50:308-310.
32. Monsel G, Ortonne N, Bagot M, Bensussan A, Dumaz N. 2009. c-Kit mutants require hypoxia-inducible factor 1alpha to transform melanocytes. Oncogene 29:227-236.
33. Morrison MA, Silveira AC, Huynh N, Jun G, Smith SE, Zacharaki F, Sato H, Loomis S, Andreoli MT, Adams SM, Radeke MJ, Jelcick AS, Yuan Y, Tsiloulis AN, Chatzoulis DZ, Silvestri G, Kotoula MG, Tsironi EE, Hollis BW, Chen R, Haider NB,Miller JW, Farrer LA, Hageman GS, Kim IK, Schaumberg DA, DeAngelis MM. 2011. Systems biology-based analysis implicates a novel role for vitamin D metabolism in the pathogenesis of age-related macular degeneration. Human Genomics 5:538-568.
34. Norval M. 2011. The challenges of UV-induced immunomodulation for children's health. Progress in Biophysics and Molecular Biology 107:323-332.
35. Park WD, Stegall MD. 2007. A meta-analysis of kidney microarray datasets: investigation of cytokine gene detection and correlation with RT-PCR and detection threshold. BMC Genomics 8:88.
36. Parkinson H, Sarkans U, Kolesnikov N, Abeygunawardena N, Burdett T, Dylag M, Emam I, Hastings E, Holloway E, Kurbatova N, Lukk M,Malone J,Mani R, Pilicheva E, Rustici G, Sharma A,Williams E, Adamusiak T, Brandizi M, Sklyar N, Brazma A. 2011. ArrayExpress updata-an archive of microarray and high-throughput sequencing-based functional genomics experiments. Nucleic Acids Research 39:D1002-D1004.
37. Parmigiani G, Garrett-Mayer ES, Anbazhagan R, Gabrielson E. 2004. A cross-study comparison of gene expression studies for the molecular classification of lung cancer. Clinical Cancer Research 10:2922-2927.
38. Pasini L, Turco MY, Luzi L, Aladowicz E, Fagiani E, Lanfrancone L. 2009. Melanoma: targeting signaling pathways and RaLP. Expert Opinion Therapeutic Targets 13:93-104.
39. Phung B, Sun J, Schepsky A, Steingrimsson E, Ronnstrand L. 2011. C-KIT signaling depends on microphthalmia-associated transcription factor for effects on cell proliferation. PLoS ONE 6:e24064.
40. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S,Mu Z, Rasalan T, Adamow M, Ritter E, Sedrak C, Jungbluth AA, Chua R, Yang AS, Roman RA, Rosner S, Benson B, Allison JP, Lesokhin AM, Gnjatic S,Wolchok JD. 2012. Immunologic correlates of the abscopal effect in a patient with melanoma. New England Journal of Medicine 366:925-931.
41. Ramasamy A,Mondry A, Holmes CC, Altman DG. 2008. Key issues in conducting a meta-analysis of gene expression microarray datasets. PLoS Medicine 5:1320-1332.
42. Rhodes DR, Barrette TR, Rubin MA, Ghosh D, Chinnaiyan AM. 2002. Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Research 62:4427-4433.
43. Rigel DS, Carucci JA. 2000. Malignant melanoma: prevention, early detection, and treatment in the 21st century. CA: A Cancer Journal for Clinicians 50:215-236.
44. Riker AI, Enkemann SA, Fodstad O, Liu S, Ren S,Morris C, Xi Y, Howell P,Metge B, Samant RS, Shevde LA, Li W, Eschrich S, Daud A, Ju J,Matta J. 2008. The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Medical Genomics 1:13.
45. Rose AE, Poliseno L,Wang J, Clark M, Pearlman A,Wang G, Vega Y, Saenz de Miera EC, Medicherla R, Christos PJ, Shapiro R, Pavlick A, Darvishian F, Zavadil J, Polsky D, Hernando E, Ostrer H, Osman I. 2011. Integrative genomics identifies molecular alterations that challenge the linear model of melanoma progression. Cancer Research 71:2561-2571.
46. Scatolini M, Grand MM, Grosso E, Venesio T, Pisacane A, Balsamo A, Sirovich R, Risio M, Chiorino G. 2010. Altered molecular pathways in melanocytic lesions. International Journal of Cancer 126:1869-1881.
47. Schramm SJ, Campain AE, Scolyer RA, Yang YH,Mann GJ. 2011. Review and cross-validation of gene expression signatures and melanoma prognosis. Journal of Investigative Dermatology 132:274-283.
48. Schubbert S, Shannon K, Bollag G. 2007. Hyperactive Ras in developmental disorders and cancer. Nature Reviews Cancer 7:295-308.
49. Smith AP, Hoek K, Becker D. 2005. Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanoma. Cancer Biology Therapy 4:1018-1029.
50. Taylor KL, Lister JA, Zeng Z, Ishizaki H, Anderson C, Kelsh RN, Jackson IL, Patton EE. 2011. Differentiated melanocyte cell division occurs in vivo and is promoted by mutations in Mitf. Development 138:3579-3589.
51. Tímár J, Gyorffy B, Rásó E. 2010. Gene signature of the metastatic potential of cutaneous melanoma: too much for too litter? Clinical and Experimental Metastasis 27:371-387.
52. Wai Wong C, Dye DE, Coombe DR. 2012. The role of immunoglobulin superfamily cell adhesion molecules in cancer metastasis. International Journal of Cell Biology Volume 2012, Article ID 340296, 9 pages.
53. Zhang H, Fu T,McGettigan S, Kumar S, Liu S, Speicher D, Schuchter L, Xu X. 2011. IL8 and cathepsin B as melanoma serum biomarkers. International Journal of Molecular Sciences 12:1505-1518.